Clinical trials: Metabolism and Elimination
- Condition Metabolism and Elimination
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Sickle Cell Disease
Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease
The objective of this study is to evaluate the pharmacokinetics of deferiprone and its 3-O-glucuronide metabolite following administration of a single 1500 mg dose of Ferriprox in patients with sickle cell disease.
- Trial name
- NCT01835496
- Testing
- single 1500 mg dose of Ferriprox
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- ApoPharma
Parkinson's Disease (PD)
An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites
The purpose of this study is to determine the rate and routes of excretion of OPC and the mass balance in urine, faeces and expired air.
- Trial name
- NCT02169427
- Testing
- OPC
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Healthy Participants
A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men
The purpose of this clinical trial is to learn about how much PF-07081532 will be taken up and processed by healthy male participants. The study consists of two parts, called study periods.
- Trial name
- NCT05652647
- Testing
- Oral [14C]PF-07081532, Oral PF-07081532 and IV [14C]PF-07081532
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus
Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease
The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in patients with Type 1 or 2 diabetes with moderate proteinuria and…
- Trial name
- PLANET 1 (NCT00296374)
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 116 sites in United States, Argentina and 9 more
- Volunteers
- 353 people
- Sponsor
- AstraZeneca
Parkinson Disease
Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 9-1067 and Metabolites
To determine the absorption, metabolism and excretion of BIA 9-1067.
- Trial name
- NCT01515891
- Testing
- BIA 9-1067
- Where
- Switzerland
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Bacterial Enteritis
A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects
To obtain absorption, metabolism and excretion data for parent drug and any metabolites.
- Trial name
- NCT02440633
- Testing
- 14C-OPS-2071
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Healthy Volunteers
Study to Assess Absolute Bioavailability (ABA) of TAK-906 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]-TAK-906 in Healthy Male Participants
The purpose of this study is to determine ABA of TAK-906 following single oral (capsule) administration of 50 milligram (mg) of TAK-906 and single intravenous (IV) microtracer dose administration of 100 microgram (μg)…
- Trial name
- NCT04454918
- Testing
- TAK-906 Oral Capsule, [14C]-TAK-906 Intravenous Infusion, [14C]-TAK-906 Oral Solution
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Healthy
A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants
The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it and also to assess the pharmacokinetics (PK), metabolism, and routes and…
- Trial name
- NCT05630287
- Testing
- [14C]-Selpercatinib, Selpercatinib
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteer
Radiolabeled [14C]PF-02341066 Study To Investigate The Absorption, Metabolism And Excretion In Healthy Male Volunteers
The rationale for this study is to investigate the absorption, metabolism and excretion of [14C]PF 02341066 and characterize plasma, fecal and urinary radioactivity, and identify any metabolites, if possible, of [14C]PF 02341066…
- Trial name
- NCT01082380
- Testing
- PF-02341066
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer
Malignant Melanoma
A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma
This open-label, non-randomized study will assess the mass balance, metabolism, routes and rates of elimination as well as efficacy and safety of RO5185426 (RG7204; PLEXXIKON; PLX4032) in previously treated or untreated patients…
- Trial name
- NCT01164891
- Testing
- RO5185426
- Where
- Switzerland
- Volunteers
- 7 people
- Sponsor
- Hoffmann-La Roche
Solid Malignancies
Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase
This Phase 1, open label, single centre, non-randomised study in patients with advanced solid malignancies consists of two parts: 1.
- Trial name
- 14C (NCT02640755)
- Testing
- [14C]AZD2014, Multiple dose AZD2014, Fulvestrant
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Healthy
A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants
The main purpose of this study is to evaluate the absorption, metabolism, and excretion (AME) profiles of pirtobrutinib (LOXO-305), to identify and characterize metabolites of pirtobrutinib (LOXO-305), and to assess the safety…
- Trial name
- NCT06180954
- Testing
- [14C]-LOXO-305, LOXO-305
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Absorption, Metabolism and Excretion of [14C]-Lasmiditan - Single Oral Dose Administration
This study will be an open-label, nonrandomized, absorption, metabolism, and excretion study of [14C]-lasmiditan administered as a 200-milligrams (mg) (approximately 100 microcuries[µCi]) oral solution to 8 healthy males and…
- Trial name
- NCT03040362
- Testing
- [14C]-lasmiditan
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Absorption, Metabolism, Excretion and Mass Balance After a Single Dose Administration of MK-0941 (MK-0941-016)(COMPLETED)
A single dose, open label study to characterize the routes of elimination and determine the mass balance of MK-0941. A single 40 mg dose of MK-0941 will be given orally to male participants with type 2 diabetes.
- Trial name
- NCT00912002
- Testing
- MK-0941
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteers
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential
This is an open-label, single-center, two part study in healthy female subjects of non-childbearing potential to investigate the absorption, metabolism, and excretion of [14C]-GDC-9545 (Part 1), the absolute bioavailability of…
- Trial name
- NCT04680273
- Testing
- [14C]-GDC-9545, GDC-9545 Solution for Infusion, GDC-9545/F12 Capsule
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy
A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy Participants
This type of study is called a radiolabeled study. For this study, LY3039478 (study drug) has been specially prepared to contain radiolabeled carbon [¹⁴C]. [¹⁴C] is a naturally occurring radioactive form of the element carbon.
- Trial name
- NCT02917733
- Testing
- LY3039478
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Kidney Function Tests
The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.
The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by Type 2 Diabetes Mellitus status and kidney function
- Trial name
- DAPASALT (NCT03152084)
- Testing
- Dapagliflozin
- Where
- 4 sites in Netherlands, Sweden
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors, Lymphomas
A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.
The purpose of this study was to determine the metabolism and elimination of 14C-lenvatinib in participants with advanced solid tumors or lymphomas, who were unsuitable for, or had failed, existing therapies.
- Trial name
- NCT02578316
- Testing
- Lenvatinib
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Eisai Inc.
Advanced Cancer
C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors
This is an open-label study being conducted to determine the metabolism and physiological disposition of radiolabeled LY2603618 after a single dose in patients with advanced and/or metastatic solid tumors.
- Trial name
- NCT01296568
- Testing
- LY2603618, Pemetrexed, Gemcitabine
- Where
- Switzerland
- Volunteers
- 3 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803
The purpose of this study is to assess the pharmacokinetics, excretion, mass balance and metabolism of PF-07265803 (formerly known as ARRY-371797) in approximately 6 healthy adult male participants.
- Trial name
- NCT05286281
- Testing
- PF-07265803
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer